Rahman Sakhawat H, Salter Gwyneth, Holmfield John H M, Larvin Michael, McMahon Michael J
Academic Unit of Surgery, University of Leeds, General Infirmary, Leeds, West Yorkshire, UK.
Crit Care Med. 2004 Dec;32(12):2457-63. doi: 10.1097/01.ccm.0000148008.99716.9c.
Soluble CD14 is derived from a membrane glycoprotein, and it enhances endothelial cytokine responses to lipopolysaccharide. We studied the role of soluble CD14 in the pathogenesis of the systemic inflammatory response associated with acute pancreatitis, to determine whether altered expression was due to a functional C-260T polymorphism in the CD14 promoter gene or altered monocyte heterogeneity.
Prospective case-matched study.
Tertiary pancreatic treatment unit in the United Kingdom.
Patients with pancreatitis and controls.
DNA from 117 patients with pancreatitis (34 severe) and 263 controls underwent CD14 genotyping using restriction fragment length polymorphism-polymerase chain reaction.
Peripheral venous blood samples at 24 and 72 hrs after the onset of abdominal pain were analyzed for sCD14 levels. Isolated peripheral blood mononuclear cells were phenotyped for CD14/CD16 receptor expression using immunofluorescence flow cytometry. Disease severity was assessed using Atlanta criteria, Acute Physiology Scores, and C-reactive protein.Soluble CD14 levels were higher in severe (24-hr median, 66.6 ng/mL; 72-hr median, 72.2 ng/mL) compared with mild attacks (24-hr median, 50.7 ng/mL; 72-hr median, 49.7 ng/mL, p < .001), although the latter was similar to controls (median, 51 ng/mL). Furthermore, soluble CD14 levels correlated with Acute Physiology Scores (p < .001) and C-reactive protein (p = .01).Peripheral blood mononuclear cells CD14++ (p = .008), CD14+/16+ (p = .003), and CD16++ (p = .015) receptor densities were all increased in severe attacks at 24 hrs. Early CD14+/16+ receptor density correlated with sCD14 (p < .001), Acute Physiology Scores (p < .001), and C-reactive protein (p = 0.006). The CD14 genotype prevalence in acute pancreatitis was similar to controls and failed to correlate with any variables studied.
Increased soluble CD14 expression is associated with the systemic inflammatory response to acute pancreatitis and an expansion of the proinflammatory CD14+/CD16+ monocyte subset. Its targeted disruption may afford some benefit in preventing the development of systemic complications.
可溶性CD14源自一种膜糖蛋白,可增强内皮细胞对脂多糖的细胞因子反应。我们研究了可溶性CD14在急性胰腺炎相关全身炎症反应发病机制中的作用,以确定其表达改变是由于CD14启动子基因中功能性C-260T多态性还是单核细胞异质性改变所致。
前瞻性病例对照研究。
英国的三级胰腺治疗单位。
胰腺炎患者和对照组。
采用限制性片段长度多态性-聚合酶链反应对117例胰腺炎患者(34例重症)和263例对照者的DNA进行CD14基因分型。
腹痛发作后24小时和72小时采集外周静脉血样本,分析可溶性CD14水平。使用免疫荧光流式细胞术对外周血单个核细胞进行CD14/CD16受体表达的表型分析。采用亚特兰大标准、急性生理学评分和C反应蛋白评估疾病严重程度。与轻症发作(24小时中位数为50.7 ng/mL;72小时中位数为49.7 ng/mL,p < 0.001)相比,重症发作(24小时中位数为66.6 ng/mL;72小时中位数为72.2 ng/mL)时可溶性CD14水平更高,不过轻症发作时的水平与对照组(中位数为51 ng/mL)相似。此外,可溶性CD14水平与急性生理学评分(p < 0.001)和C反应蛋白(p = 0.01)相关。重症发作24小时时外周血单个核细胞CD14++(p = 0.008)、CD14+/16+(p = 0.003)和CD16++(p = 0.015)受体密度均增加。早期CD14+/16+受体密度与可溶性CD14(p < 0.001)、急性生理学评分(p < 0.001)和C反应蛋白(p = 0.006)相关。急性胰腺炎患者中CD14基因型患病率与对照组相似,且与所研究的任何变量均无相关性。
可溶性CD14表达增加与急性胰腺炎的全身炎症反应及促炎CD14+/CD16+单核细胞亚群的扩增有关。靶向阻断可溶性CD14可能对预防全身并发症的发生有益。